


### quantification & biomarker studies



 $1000\ {\rm cases},\ {\rm DATSCAN}\ [{\rm SPECT}],\ 7{\rm -classes}\ {\rm clinical}\ {\rm visual}\ {\rm reading}$ 


4 independent quantification methods

**Dopaminergic imaging** 

### DATSCAN [SPECT]

Target: neurodegeneration linked to Parkinson's disease and related symptoms

Collaboration with: Osp. Univ. di Padova (PD)



#### doi:10.1093/brain/awaa365

#### BRAIN 2020: Page I of I0

aPutamenAs aCaudateMAH aPCratio.


aPCratio<sub>R</sub> aCaudateLAH


Constipation

Hyposmia

#### Dopaminergic imaging and clinical predictors for phenoconversion of **REM** sleep behaviour disorder

Dario Arnaldi,<sup>1,2</sup> Andrea Chincarini,<sup>3</sup> Michele T. Hu,<sup>4</sup> © Karel Sonka,<sup>5</sup> Bra Tomoyuki Miyamoto,<sup>7</sup> Monica Puligheddu,<sup>8</sup> Valérie Cochen De Cock,<sup>9</sup> Michele Terzaghi,<sup>10,11</sup> Giuseppe Plazzi,<sup>12,13</sup> Naoko Tachibana,<sup>14</sup> Silvia Mo Michal Rolinski,<sup>4,17</sup> Petr Dusek,<sup>5</sup> Val Lowe,<sup>18</sup> Masayuki Miyamoto,<sup>19</sup> Michi <sup>a</sup>PutamentAH Delphine de Verbizier,<sup>20</sup> Irene Bossert,<sup>21</sup> Elena Antelmi,<sup>12,22</sup> Riccardo M <sup>©</sup> Thomas R. Barber<sup>4</sup> Jiří Tirnka,<sup>23</sup> Toji Miyagawa,<sup>6</sup> Alessandra Serra,<sup>24</sup> Fa <sup>©</sup> Matteo Bauckneht,<sup>15,16</sup> Kevin M. Bradley,<sup>25</sup> <sup>©</sup> David Zogala,<sup>23</sup> Daniel R. <sup>Acudateks</sup>





#### **DATSCAN + NPSY + Clinics**

in collaboration with: the international group of RBD

SPECT quantification analysis + ranking the most significant predictors of phenoconversion + survival analysis up to 9 years



NeuroImage: Clinical Volume 23, 2019, 101846



Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)

A. Chincarini ª 🛠 🖾, E. Peira <sup>a, d</sup>, S. Morbelli <sup>b, c</sup>, M. Pardini <sup>c, d</sup>, M. Bauckneht <sup>c</sup>, J. Arbizu <sup>c</sup>, M. Castelo-Branco <sup>f</sup>, K.A.

Büsi Original Article | Published: 25 January 2020 Gari

A kinetics-based approach to amyloid PET semiquantification

A. Chincarini 🖂, E. Peira, M. Corosu, S. Morbelli, M. Bauckneht, S. Capitanio, M. Pardini, D. Arnaldi, C. Vellani, D. D'Ambrosio, V. Garibotto, F. Assal, B. Paghera, G. Savelli, A. Stefanelli, U. P. Guerra & F. Nobili

European Journal of Nuclear Medicine and Molecular Imaging (2020) | Cite this article

Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context.

Nobili F<sup>1</sup><sup>SE</sup>, Cagnin A<sup>2</sup>, Calcagni ML<sup>3</sup>, Chincarini A<sup>4</sup>, Guerra UP<sup>5</sup>, Morbelli S<sup>6</sup><sup>OD</sup>, Padovani A<sup>7</sup>, Paghera B<sup>8</sup>, Pappatà S<sup>9</sup>, Parnetti L<sup>10</sup>, Sestini S<sup>11</sup>, Schillaci O<sup>12</sup> *Journal of Nuclear Medicine and Molecular Imaging* 


## **Amyloid imaging**

latest papers on quantification, clinical validation, patterns

in collaboration with: italian IRCCS, EADC, AIM, EANM

(INFN CSN5, 2019





SUVr-independent evaluation of brain amyloidosis, Chincarini et. al, Journal of Alzheimer's Disease, Vol. 54-4 (2016)

Approaches to semi-quantification: beyond SUVr in amyloid imaging, European Conference on Clinical Neuroimaging, Roma (2016)

Semi-quantification and grading of amyloid PET, Chincarini et. al, Neuroimage Clinical, (2019)

> bias on higher intensities




Quantification and ranking in amyloid-PET, R. Gianeri, Master in


## TDr



REQUIREMENT: needs the early scan (0-5' from injection)








5. 2019


\* Chincarini et al. Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). NeuroIm. Clin. 2019


## Clinical correlates



under review at Journal of Alzheimer's Disease

5.2019






#### Neuropsychology

Innovative use of NPSY tests in the discrimination of Alzheimer concomitant pathologies (10 clinical cohorts)

#### multivariate KDE + odds ratio analysis

in collaboration with: IRCCS GE

paper submitted to Alzh. res. & therapy [IF 6.1]






#### Towards alternative tests for brain amyloidosis



Aknowledgements to: Prof. Flavio Nobili Doc. Francesco Famà Prof. Silvia Morbelli



Candidate: Gloria Pedemonte

Supervisor: Prof. Andrea Chincarini

#### **EEG analysis**

AMYLOID


Wilcoxon rank sum test pv = 0.000

0.5

EEG combined featur

DL + quantification exploratory model (autoencoders) to link EEG patterns to amyloid & FDG impairment

### in collaboration with: IRCCS GE paper under preparation



### technology transfer

# DORIAN technologies



#### Founders:

Andrea Chincarini Francesco Sensi Paolo Bosco Mirko Corosu Enrico Peira Ruben Gianeri

Med advisors:

**Flavio Nobili** Silvia Morbelli

**Diego Cecchin** Davide Poggiali

**Stelvio Sestini** Luca Fedeli

your key to better data analysis

Andrea Chincarini

INFN

## mission: NM in neurology

clinical practice

medical research

medical training

pharmaceutical trials

today

tomorrow

personalized medicine

screening

certification as medical device To **develop** and distribute **reliable AI-driven analyses** to improve **diagnostic impact**, **reliability** and clinical **confidence**.

Two analysis pipelines currently available:

- DAT SPECT (datscan & striascan)
- amyloid-PET (all 3 fluorinated tracers)

Future efforts to include:

- FDG
- FDOPA
- tau-PET
- T1-MRI atrophy pattern
- T2-MRI WM lesions


**W**e provide a comprehensive learning environment to approach automatic analysis of amyloid PET in a typical clinical setting

We help to write a more informed diagnosis report

#### we help reducing the diagnostic error

We provide on-demand continuous medical training on specific pathology

We comply with NM societies requirements



SN25\*

#### **Training on amyPET**

[2017 - ]

AIMN national school of Nuclear Medicine in Neurology (Pesaro, September 2006- )